Page 93 - 南京医科大学自然版
P. 93

第44卷第4期               喻 悦,王瑜亮,张 晓. 葡萄糖代谢重编程在胰腺癌耐药中的研究进展[J].
                  2024年4月                   南京医科大学学报(自然科学版),2024,44(04):524-535,572                     ·531 ·


                                            表1 靶向糖代谢通路在胰腺癌治疗中的临床试验
                          Table 1 Clinical trials targeted glucose metabolic pathway in the treatment of pancreatic cancer
                                                                                                         Phase of
                 Item                                     Pancreatic                         Route of drug
                          Period         Institution                        Intervention                 clinical
                number                                  cancer category                      administration
                                                                                                           trial
                1     2004.02-2008.07 University of Miami Syl⁃ Later period or 2⁃DG:2 mg/kg,every week;  Oral and  Ⅰ
                                                                                    2
                                    vester  Comprehensive metastasis of pan⁃ Docetaxel:30 mg/m(3 times/  intravenous
                                    Cancer Center,USA  creatic cancer  4 weeks)                injection
                2     2007.01-2009.05 Dana⁃Farber Cancer In⁃ Metastasis of pan⁃ RAD001:10 mg/d   Oral      Ⅱ
                                    stitute,USA        creatic cancer
                3     2008.04-2011.01 Universiteit van Amster⁃ Pancreatic  can⁃ Ivolimus:10 mg/d;Capecitabine:  Oral  Ⅰ
                                                                             2
                                    dam,the Netherlands  cer ECOG status 500 mg/m (administered for        &Ⅱ
                                                       0⁃2           14 days,stopped for 7 days,
                                                                     dose increased)

                                                                                      2
                4     2009.09-2015.06 Novartis  Pharmaceuti⁃ Pancreatic neuro⁃ Paretide LAR:60 mg/m(28 d)  Intravenous  Ⅱ
                                    cals,USA           endocrine tumors                        injection
                5     2009.11-2011.03 ERYtech Pharma,  Later period of  ERY⁃ASP:25,50,100,150 U/kg  Intravenous  Ⅰ
                                    France             pancreaticcancer,(dose escalation)      injection
                                                       unresectable,in⁃
                                                       vasion of superior
                                                       mesenteric artery
                                                      (stageⅢ)or meta⁃
                                                       static(stage Ⅳ)

                                                                                  2
                6     2013.04-2016.01 Yale University,USA  Metastatic  pan⁃ CPI⁃613:500 mg/m(≤4 weeks), Intravenous  Ⅰ
                                                       creatic cancer  2  times  dose  increased  injection
                                                                    ( > 4 weeks);Oxaliplatin:
                                                                           2
                                                                     65 mg/m(2 weeks);Calcium
                                                                     folinat:400 mg/m(2 weeks);
                                                                                  2
                                                                     Irinotecan:140 mg/m(2 weeks);
                                                                                    2
                                                                     5⁃Fu:400 mg/m(2 weeks)
                                                                                2
                7     2013.05-2017.09 UT Southwestern  Pancreatic cancer Pioglitazone:45 mg/d(8 weeks)  Oral  Ⅱ
                                    Medical Center,USA  ECOG status 0⁃2
                8     2014.07-2017.11 ERYtech Pharma,USA  Advanced or me⁃ ERY⁃ASP:100 U/kg(D3,D17, Intravenous  Ⅱ
                                                       tastaticpancreatic D28);Gemcitabine:1 000 mg/m 2  injection
                                                       exocrine  adeno⁃ (1 weeks);mFOLFOX6[Oxali⁃
                                                                                 2
                                                       carcinoma     platin:85 mg/m(2 weeks);
                                                                     Calcium folinat: 400 mg/m 2
                                                                    (2 weeks);5⁃Fu:400 mg/m 2
                                                                    (2 weeks);5⁃Fu:2 400 mg/m 2
                                                                    (continuous intravenous infu⁃
                                                                     sion for 46 hours)]

                9     2016.03-2022.05 University of Texas  Metastatic,unre⁃ ARQ761:195 mg or 290 mg or  Intravenous  Ⅰ
                                    Southwestern Medical  sectable or recur⁃ 390 mg(D1,D15);Gemcitabine:  injection
                                                                              2
                                    Center,USA         rent pancreatic  1 000 mg/m(D1,D8,D15);
                                                       cancer        Albumin bound paclitaxel:
                                                                     125 mg/m(D1,D8,D15)
                                                                            2
   88   89   90   91   92   93   94   95   96   97   98